ALNY - ALNYLAM PHARMACEUTICALS, INC.
IEX Last Trade
238.225
-1.285 -0.539%
Share volume: 7,794
Last Updated: Fri 27 Dec 2024 05:29:30 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.39%
PREVIOUS CLOSE
CHG
CHG%
$239.51
-1.29
-0.54%
View ratios
| Fiscal Date | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
| Report Date | 2022-10-27 | 2023-02-23 | 2023-05-04 | 2023-08-03 | 2023-11-02 | 2024-02-15 | 2024-05-02 | 2024-08-01 | |
| Assets | |||||||||
| Total Assets | 3.535 B | 3.546 B | 3.392 B | 3.402 B | 3.839 B | 3.830 B | 3.824 B | 4.010 B | |
| Current Assets | 2.691 B | 2.692 B | 2.541 B | 2.524 B | 2.985 B | 2.983 B | 2.989 B | 3.173 B | |
| Inventories | 115.489 M | 128.962 M | 131.879 M | 100.453 M | 95.771 M | 89.146 M | 93.988 M | 83.981 M | |
| Other Current Assets | 125.516 M | 132.916 M | 119.030 M | 145.452 M | 157.958 M | 126.382 M | 201.960 M | 154.745 M | |
| Short Term Investments | 125.516 M | 132.916 M | 119.030 M | 145.452 M | 157.958 M | 126.382 M | 201.960 M | 154.745 M | |
| Total Receivables | 184.513 M | 237.963 M | 219.434 M | 220.635 M | 325.445 M | 327.787 M | 321.377 M | 309.481 M | |
| Current Cash | 2.265 B | 2.192 B | 2.071 B | 2.058 B | 2.406 B | 2.439 B | 2.371 B | 2.625 B | |
| Total Non-current Assets | 844.408 M | 854.112 M | 850.922 M | 878.349 M | 853.621 M | 847.183 M | 835.779 M | 836.778 M | |
| Property Plant Equipment | 514.821 M | 523.494 M | 523.032 M | 527.474 M | 525.591 M | 526.057 M | 523.460 M | 517.159 M | |
| Other Assets | 61.396 M | 66.092 M | 63.453 M | 92.686 M | 75.155 M | 72.003 M | 67.461 M | 71.925 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 3.535 B | 3.546 B | 3.392 B | 3.402 B | 3.839 B | 3.830 B | 3.824 B | 4.010 B | |
| Total liabilities | 3.603 B | 3.705 B | 3.651 B | 3.811 B | 4.005 B | 4.051 B | 4.044 B | 4.013 B | |
| Total current liabilities | 772.791 M | 767.915 M | 673.391 M | 788.639 M | 949.785 M | 967.786 M | 941.709 M | 1.055 B | |
| Accounts Payable | 40.572 M | 98.094 M | 62.237 M | 59.746 M | 73.840 M | 55.519 M | 78.148 M | 73.980 M | |
| Other liabilities | 1.548 B | 1.658 B | 1.701 B | 1.750 B | 1.788 B | 1.819 B | 1.842 B | 1.695 B | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 1.016 B | 1.017 B | 1.018 B | 1.019 B | 1.020 B | 1.021 B | 1.022 B | 1.023 B | |
| Other liabilities | 1.548 B | 1.658 B | 1.701 B | 1.750 B | 1.788 B | 1.819 B | 1.842 B | 1.695 B | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | -67.638 M | -158.223 M | -259.240 M | -408.131 M | -165.866 M | -220.644 M | -219.272 M | -3.067 M | |
| Common stock | 122.166 M | 123.301 M | 124.111 M | 124.659 M | 125.220 M | 125.634 M | 126.138 M | 126.733 M | |
| Retained earnings | -6.362 B | -6.569 B | -6.743 B | -7.019 B | -6.872 B | -7.010 B | -7.076 B | -7.092 B |